UK
UK Pet Pharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Product, Animal, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
UK · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany at $806.1 Mn.
Italy at 6.8% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$295.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $509.8 Mn | — | — |
| 2025 (base) | $535.3 Mn | +$25.5 Mn | — |
| 2026 (forecast) | $562.0 Mn | +$26.8 Mn | +5% |
| 2027 (forecast) | $590.1 Mn | +$28.1 Mn | +10.3% |
| 2028 (forecast) | $619.6 Mn | +$29.5 Mn | +15.8% |
| 2029 (forecast) | $650.6 Mn | +$31.0 Mn | +21.6% |
| 2030 (forecast) | $683.1 Mn | +$32.5 Mn | +27.6% |
| 2031 (forecast) | $717.3 Mn | +$34.2 Mn | +34% |
| 2032 (forecast) | $753.2 Mn | +$35.9 Mn | +40.7% |
| 2033 (forecast) | $790.8 Mn | +$37.7 Mn | +47.7% |
| 2034 (forecast) | $830.4 Mn | +$39.5 Mn | +55.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$9.85 Bn
China
$2.09 Bn
Canada
$1.83 Bn
Japan
$1.48 Bn
Germany
$806.1 Mn
France
$702.2 Mn
UK (this report)
$535.3 Mn
Italy
$551.1 Mn
Ecuador
$533.3 Mn
Brazil
$521.7 Mn
Spain
$447.8 Mn
Saudi Arabia
$437.5 Mn
India
$380.1 Mn
Mexico
$345.1 Mn
Australia
$245.7 Mn
Russia
$234.6 Mn
New Zealand
$210.8 Mn
South Africa
$175.2 Mn
UAE
$102.1 Mn
Egypt
$62.0 Mn
Philippines
$46.5 Mn
Malaysia
$34.5 Mn
Hong Kong
$33.3 Mn
Singapore
$31.1 Mn
Thailand
$25.4 Mn
Kenya
$18.6 Mn
Pet pharmaceuticals treat dogs, cats and other pets for parasites, pain, allergies, infections and chronic diseases.
Key segments of the pet Pharmaceuticals market include product (Parasiticides, Anti-Inflammatories and Antibiotics) and animal (Dogs, Cats and Others).
More pets per household, owners treating pets as family, livestock disease risks and the One Health approach linking animal and human health are driving the pet Pharmaceuticals market.
Pet insurance, diagnostics and vaccines for emerging animal diseases give the pet Pharmaceuticals market room to grow.
Cost-sensitive farmers, fewer vets in rural areas, rules on antibiotic use in animals and slow approvals hold back the pet Pharmaceuticals market.
The pet Pharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pet Pharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.
What doctors and scientists are doing in Pet Pharmaceuticals right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
UK · 2 shared keywords
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
OTC & Nutraceuticals · UK
Healthcare Services · UK
Medical Devices · UK
Digital Health · UK
Healthcare Services · UK
Public Health · Global